IDO

IDO inhibitors block indoleamine 2,3-dioxygenase (IDO), the heme enzyme that starts tryptophan breakdown. By depleting tryptophan and producing kynurenine metabolites, IDO dampens local T cell responses. In 1998, blocking tryptophan catabolism in pregnant mice caused T cell-mediated rejection of allogeneic fetuses. Work published in 2003 showed that tumor cells expressing IDO resist immune rejection in mice. Epacadostat, BMS-986205 and LY-3381916 are IDO1 inhibitors used in tumor immunology studies. Indoximod, a tryptophan analog, acts on the same pathway, whereas GNF-PF-3777 targets the related enzyme IDO2. IDO/TDO-IN-1 also inhibits tryptophan 2,3-dioxygenase (TDO), the liver enzyme that catalyzes the same reaction.

3 Items

  • PROTAC IDO1 Degrader-1
    Cat. No.
    A24852

    PROTAC IDO1 Degrader-1

    PROTAC IDO1 Degrader-1 is a novel compound targeting indoleamine 2,3-dioxygenase 1 (IDO1) through the engagement of Cereblon E3 ligase, facilitating its ubiquitination and subsequent degradation. With a reported DC50 of 2.84 μM, this degrader enhances the anti-tumor efficacy of HER2 CAR-T cells, making it a valuable tool for research in cancer immunotherapy and targeted degradation methods. Its ability to modulate IDO1 levels opens avenues for investigations into metabolic regulation and tumor microenvironment interactions.

    1 mg
    $270.00
    5 mg
    $570.00
    All 6 sizes
  • NU227326
    Cat. No.
    A75732

    NU227326

    NU227326 is a potent IDO1 PROTAC degrader designed to penetrate the blood-brain barrier, exhibiting a DC50 of 4.5 nM in HiBiT degradation assays. It effectively degrades IDO1 in human glioblastoma cell lines U87 and GBM43, with DC50 values of 7.1 nM and 11.8 nM, respectively, as demonstrated in Western blot assays. This compound is valuable for research into various malignancies, including glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer.

    1 mg
    $575.00
    5 mg
    $1,475.00
    All 5 sizes
  • NU223612
    Cat. No.
    A75734

    NU223612

    NU223612 is a selective PROTAC designed to target and degrade indoleamine 2,3-dioxygenase 1 (IDO1) through CRBN-mediated proteasomal degradation, exhibiting a Kd of 640 nM. With a binding affinity for CRBN of 290 nM, NU223612 effectively reduces IDO1 protein levels, making it a valuable tool in the study of immune modulation and tumor microenvironments. Additionally, NU223612 demonstrates the ability to cross the blood-brain barrier, enhancing its potential utility in neurobiological research.

    Out of stock

    All 3 sizes

3 Items

Added to your cart

View Cart Checkout

    Loading...